Drug Profile
Research programme: mannose receptor-targeted therapeutic agents - Navidea Biopharmaceuticals
Alternative Names: Cy3-Manocept-doxorubicin; Cy3-manocept-therapeutics; MT 1000; MT 1001; MT 2000; MT 2001; MT-1002; MT-2002Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Navidea Biopharmaceuticals
- Developer Macrophage Therapeutics; Navidea Biopharmaceuticals; Unknown
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antituberculars; Antivirals; Cardiovascular therapies; Hepatoprotectants; Immunotherapies; Neuroprotectants; Steroids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; CNS disorders; Crohn's disease; Infections; Inflammatory bowel diseases; Kaposi's sarcoma; Non-alcoholic fatty liver disease
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Nov 2022 Preclinical pharmacodynamic data in Cancer released by Navidea
- 15 Aug 2022 Navidea Biopharmaceuticals receives notification of issuance of patent for compounds, compositions and methods for using it in diagnosis and treating Leishmaniasis, in USA